Trump’s Rescheduling Order Is Real — and It’s Already Creating More Confusion Than Clarity

WASHINGTON — The Trump administration made good on one of its more consequential cannabis promises last week, issuing an executive action aimed at reclassifying marijuana under federal law. But according to policy experts and industry attorneys who have been parsing the order since it landed, the move is a partial rescheduling — not the clean Schedule III transfer the industry had been anticipating — and the gap between expectation and legal reality is already generating significant confusion among operators, compliance officers, and state regulators.

“This makes an already complex process more confusing,” one legal expert told The Guardian, capturing what has become the dominant sentiment inside the cannabis policy corridor since the order dropped.

What the Order Actually Does — and What It Doesn’t

The Trump administration’s action does not complete the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act. That process, initiated under the Biden administration following a landmark HHS recommendation in 2023, remains formally incomplete. The DEA still controls the rulemaking calendar, and a final rule has not been published.

What the executive order does is direct the Department of Justice to treat state-licensed medical cannabis businesses as if they are operating in a Schedule III environment for specific federal purposes — most notably tax enforcement. The order is an administrative posture shift, not a statutory rewrite. Cannabis remains a Schedule I substance under the CSA until the DEA publishes a final rule in the Federal Register and the comment period closes.

That distinction matters enormously. An executive directive can instruct federal agencies to deprioritize enforcement or issue guidance. It cannot override statutory scheduling, and it cannot by itself eliminate the legal and financial consequences that flow from Schedule I classification — consequences that have cost the industry billions in punitive tax treatment under Section 280E of the Internal Revenue Code.

Treasury and IRS Signal Relief — Eventually

The day after the executive action, the Treasury Department and the IRS issued a joint press release acknowledging the shift. The two agencies said they “expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry” and pledged that additional guidance on 280E tax treatment would be forthcoming.

That statement is being read carefully — and cautiously — across the industry. Treasury did not say 280E no longer applies. It said guidance is coming. For operators who have been paying effective tax rates of 60 to 80 percent because they cannot deduct ordinary business expenses under 280E, the promise of forthcoming guidance is meaningful, but it is not the same as relief.

The practical timeline for that guidance remains unclear. Tax attorneys advising cannabis clients have been counseling operators to continue filing as if 280E applies until the IRS formally issues a revenue ruling or amended guidance. The risk of filing on the assumption that 280E has been suspended — without a definitive IRS ruling — is considered substantial.

The Partial Rescheduling Problem

The “partial rescheduling” characterization is the crux of the policy dispute now playing out across Washington.

The administration’s approach appears to be designed to deliver a political win — the President can say he moved on cannabis — while avoiding the full statutory and regulatory implications of a completed Schedule III transfer. Completing the rescheduling through formal DEA rulemaking would open the door to federally legal medical cannabis dispensing, trigger new FDA regulatory obligations, potentially disrupt DEA production quotas and pharmaceutical supply chains, and require Congress to confront cannabis banking in a more direct way than it has been willing to do.

By issuing an executive order that directs agency behavior without finalizing the rule, the administration can claim credit while deferring the hard downstream decisions. The result, as critics point out, is a federal posture that is neither Schedule I nor Schedule III in practice — it’s a jurisdictional grey zone that the courts have not yet been asked to interpret.

For state-licensed operators, this creates a compliance nightmare. Their businesses exist in a patchwork of state-legal, federally-tolerated frameworks. When federal agency behavior shifts based on executive direction rather than statute or finalized rule, compliance counsel cannot give clean advice. Operators don’t know which enforcement posture a given federal agency will take on a given day, and that uncertainty has a real cost — in legal fees, in banking risk premiums, and in the ongoing reluctance of institutional capital to enter the sector at scale.

What Has to Happen Next

For the rescheduling to be legally complete, the DEA must publish a final rule in the Federal Register. The DEA received more than 40,000 public comments during the formal comment period — a record for any DEA rulemaking. The agency has provided no public timeline for when a final rule might be issued, and the backlog of administrative work required to process that volume of comment before finalizing the rule is substantial.

The executive order does not accelerate that timeline. It does not give the DEA new authority to skip comment processing or abbreviate the rulemaking. Under the Administrative Procedure Act, the final rule must be supported by a reasoned response to the substantive comments received — a process that takes months even under favorable administrative conditions.

Absent a final rule, cannabis banking reform remains stalled in the same place it has occupied for years. The SAFE Banking Act — which would grant depository institutions a safe harbor for servicing cannabis businesses — has passed the House multiple times and died in the Senate. The rescheduling order does not change that calculus. Banks are not waiting for executive direction on agency enforcement posture; they are waiting for statutory protection that only Congress can provide.

The Political Calculus

The Trump administration’s cannabis moves this spring have been consistent in their approach: deliver visible action, claim political credit, avoid statutory commitment. The President’s social media posts on hemp-derived CBD last week followed the same pattern — a public endorsement with no legislative proposal attached.

This is not cynicism for its own sake. The administration is navigating a Republican caucus that is not uniformly enthusiastic about federal cannabis liberalization, a banking sector that will not move without statutory certainty, and a DEA bureaucracy with its own institutional interests in the rescheduling timeline. The executive order is the tool available given those constraints.

But for the industry, the consequences of that political calculus are concrete and ongoing. Another quarter will pass with 280E in legal limbo. Another round of institutional investors will watch from the sidelines. Another cohort of cannabis operators will carry federal tax burdens that their peers in any other industry would find incomprehensible.

The administration delivered movement. Whether it delivered progress is a different question — and the answer, for now, is that no one in Washington is quite sure.

Ethan Vale covers federal cannabis legislation, DEA and FDA policy, and the U.S. Congress for CannabisInquirer.com. He is based in Washington, D.C.